Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia
about
Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasmsLeukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding proteinMouse models of neurofibromatosis 1 and 2.Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantationRas-induced cellular events (review)PU.1, interferon regulatory factor (IRF) 2, and the interferon consensus sequence-binding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cellsGermline KRAS mutations cause Noonan syndromeLoss of the nf1 tumor suppressor gene decreases fas antigen expression in myeloid cellsThe neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 miceGenetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivoNf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferaseOncogenic Kras expression in postmitotic neurons leads to S100A8-S100A9 protein overexpression and gliosisThe Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblastsHyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functionsRas dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model.Genetic predispositions and childhood cancer.Mouse models of human familial cancer syndromes.Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by RasRetroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice.Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.Myelodysplasia and myeloproliferative disorders in childhood: an update.Retroviral integration at the Epi1 locus cooperates with Nf1 gene loss in the progression to acute myeloid leukemia.Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein.Mast cells and the neurofibroma microenvironmentNF1 inactivation in adult acute myelogenous leukemiaMalignancy: Tumor Suppressor Gene Aberrations in Acute Myelogenous Leukemia.Integration of SNP and mRNA arrays with microRNA profiling reveals that MiR-370 is upregulated and targets NF1 in acute myeloid leukemia.Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts.Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.A novel cytokine pathway suppresses glial cell melanogenesis after injury to adult nerve.PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant miceSomatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cellsHuman somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.Scientific and clinical opportunities for modeling blood disorders with embryonic stem cellsSkin-derived precursor cells as an in vitro modelling tool for the study of type 1 neurofibromatosis
P2860
Q24530021-497B39C3-7D49-4DFF-ACF8-AF5ECE328251Q24670487-3FC47DB0-4577-4A1F-A9AB-6A63552DFC85Q24682869-9A75C274-7FCF-4B60-97A4-B965F83A585AQ26851000-F23B9FCB-411F-46A0-9B9A-F5080B91029BQ28138814-222F0003-A844-4BBE-B76F-1E4DB9A4AC34Q28281520-79D8AC2F-2DD2-409F-99DD-B5C815152A3DQ28297024-2EFE1362-3D4A-4C39-AA61-5476BE844D82Q28504730-B44C62C8-80D1-42FC-AB67-FFCF5EEB2204Q28511045-8481E56F-EF22-458F-A789-887E2C42410AQ28585229-A1489EB4-B7EB-4A1F-8401-D2D4A7A676C5Q28588037-5C8AF051-D413-4385-A05C-7E7CF1631091Q28589373-331DD362-D34F-4CC3-B6D8-1AA417C81471Q28590121-EB43557F-D149-4D85-BAEF-FCF268E2F72DQ28593384-4ECC08E3-4B37-41A3-8518-69E1DEFC29B8Q30375214-13818648-7CB5-4B93-B3EC-022EF6538590Q30499276-D4C96586-978F-4646-B8A6-E91AAB140B87Q33204054-B2A27494-AEBB-4381-B988-A8F7D5559061Q33241589-287CFA02-CADD-4B84-8701-1A92A41981EAQ33677450-13CABB7B-150E-4A91-A1FF-FDFA2F8FF0B4Q33718764-AD66F25F-6081-4F9A-8261-98C125AADF31Q33722741-FE8B1C2A-0799-4378-B4A7-3ED4FF5ECBDBQ33770597-5835481C-9ACA-49D4-92A7-127D63A7DAB3Q33845906-3C5E26DA-D076-4212-8EB2-CF7693658583Q33884193-65452392-2C72-40A3-8FD3-E8BD01905F68Q34022409-D3DE45F9-E7F5-4A66-A32C-769BF4F3CE1EQ34065032-8B7EDA60-B88E-465F-AAF0-DD877FC32046Q34278271-E8D142C3-0FA9-483F-BD90-198A0F3F263AQ34451050-10CA992C-C636-4B39-B4E0-2B068B82DFECQ34734319-7EBE62F4-FC00-4720-BCB2-4AFA7B5E3893Q35081389-0F723D41-44F2-4D3B-A13E-6A33A785C898Q35186888-E2B5E94A-6E1B-4951-9D47-1577673CC51BQ35538007-2110F074-E64A-4DF2-9076-6D22162A573AQ35616065-C37FFF04-A3B9-4CA5-94F7-39D1EF74759AQ35628894-12ED0D1C-D5C3-4D11-8169-B3A3D9DEBABAQ35735401-AF95B6C3-1540-49AA-9A76-822EE0EA1FEDQ35804477-F3F90EEB-9268-4D90-89A8-A9AC778593E8Q35847470-B47804B9-8D11-402D-BE73-411B13A8623BQ35847802-3027B041-733A-4F4C-95C4-471B7C6ADEF1Q35848553-81EF7909-86D6-415D-96D2-772011E91C79Q35898391-A7759AD0-3C09-4361-8F2B-2ACC51716D77
P2860
Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia
description
1996 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
articolo scientifico
@it
artículu científicu espublizáu en 1996
@ast
im Februar 1996 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1996/02/01)
@sk
vědecký článek publikovaný v roce 1996
@cs
wetenschappelijk artikel (gepubliceerd op 1996/02/01)
@nl
наукова стаття, опублікована в лютому 1996
@uk
name
Nf1 deficiency causes Ras-medi ...... and chronic myeloid leukaemia
@ast
Nf1 deficiency causes Ras-medi ...... and chronic myeloid leukaemia
@en
Nf1 deficiency causes Ras-medi ...... and chronic myeloid leukaemia
@nl
type
label
Nf1 deficiency causes Ras-medi ...... and chronic myeloid leukaemia
@ast
Nf1 deficiency causes Ras-medi ...... and chronic myeloid leukaemia
@en
Nf1 deficiency causes Ras-medi ...... and chronic myeloid leukaemia
@nl
prefLabel
Nf1 deficiency causes Ras-medi ...... and chronic myeloid leukaemia
@ast
Nf1 deficiency causes Ras-medi ...... and chronic myeloid leukaemia
@en
Nf1 deficiency causes Ras-medi ...... and chronic myeloid leukaemia
@nl
P2093
P2860
P921
P356
P1433
P1476
Nf1 deficiency causes Ras-medi ...... and chronic myeloid leukaemia
@en
P2093
C. I. Brannan
D. A. Largaespada
N. A. Jenkins
N. G. Copeland
P2860
P2888
P304
P356
10.1038/NG0296-137
P407
P577
1996-02-01T00:00:00Z